An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Completed · Phase 3

Conditions studied: Epilepsy

In brief

The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.

Key facts

Study ID

NCT00761774

Run by

UCB Pharma

People needed

108

Starts

2008-11-01

Expected to finish

2017-03-01

Last updated by the study team

2018-07-11

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial.
• Subjects from whom the Investigator believes a reasonable potential benefit from the long-term administration of brivaracetam may be expected.

You may not qualify if…

• Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.

Where it is running

• 281 — Fresno, California, United States
• 288 — Pasadena, California, United States
• 240 — Riverside, California, United States
• 245 — Sacramento, California, United States
• 285 — Peoria, Illinois, United States
• 224 — Indianapolis, Indiana, United States
• 266 — Lexington, Kentucky, United States
• 231 — Waldorf, Maryland, United States
• 278 — Burlington, Massachusetts, United States
• 270 — New York, New York, United States
• 284 — Hickory, North Carolina, United States
• 241 — Columbus, Ohio, United States
• 265 — Oklahoma City, Oklahoma, United States
• 297 — Germantown, Tennessee, United States
• 260 — Austin, Texas, United States
• 236 — Bedford, Texas, United States
• 267 — Dallas, Texas, United States
• 268 — Houston, Texas, United States
• 211 — Layton, Utah, United States
• 235 — Ogden, Utah, United States
• 218 — Burlington, Vermont, United States
• 279 — Danville, Virginia, United States
• 277 — Charleston, West Virginia, United States
• 213 — Marshfield, Wisconsin, United States
• 304 — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.